|
Rena Li, Ph.D.
Sun Health Research Institute
Sun City, AZ
Title:
Estrogen And Its Receptors In BACE1 Regulation: From Cells To Mice
Non-Technical Title:
Estrogen In Alzheimer’s Disease
Duration:
April 1, 2009 - March 31, 2012
Co-Investigator(s):
Yong Shen, M.D., Ph.D.
Sun Health Research Institute
|
Summary: Reduction of estrogen in postmenopausal women might cause a higher risk of developing Alzheimer's disease (AD). Studies show that inhibition of beta-secretase (BACE1) might play a major role in preventing AD. Our study on estrogen and estrogen receptors in BACE1 regulation will not only provide better understanding of molecular mechanisms of estrogen in preventing AD, but also provide scientific evidence for new drug development.
More details
Program: Alzheimer's Disease
Award Type: Standard
$399,761
|
Yueming Li, Ph.D.
Sloan-Kettering Institute for Cancer Research
New York, NY
Title:
Effects of aging and gender on gamma-secretase
Non-Technical Title:
Aging and gamma-secretase
Duration:
April 1, 2010 - March 31, 2013
|
Summary: The vast majority of Alzheimer’s disease (AD) is sporadic in nature and has no known genetic basis. Aging and gender are common risk factors for the development of AD. This project will elucidate the role of aging and gender in the modulation of gamma-secretase that is linked with AD.
More details
Program: Alzheimer's Disease
Award Type: Standard
$400,000
|
Dezhi Liao, Ph.D.
University of Minnesota
Minneapolis, MN
Title:
Abnormal Presence Of Tau Proteins In Dendritic Spines
Non-Technical Title:
Tau In A Wrong Place
Duration:
April 1, 2009 - March 31, 2011
Co-Investigator(s):
Karen Hsiao Ashe, M.D., Ph.D.
University of Minnesota
|
Summary: We will test the novel concept that specific chemical modification drives unual targeting of Alzheimer’s-linked “tau” proteins to the dendritic spines of neurons. This targeting might provide a mechanistic link between amyloid and tauopathies, hallmarks of the Alzheimer’s disease (AD) process. Therefore, the successful completion of this project will provide a more complete mechanistic model for AD than available at present.
More details
Program: Alzheimer's Disease
Award Type: Pilot
$150,000
|
Paul Lombroso, M.D.
Yale University
New Haven, CT
Title:
The Role of STEP in Alzheimer's Disease
Non-Technical Title:
New Targets for the Treatment of Alzheimer's Disease
Duration:
April 1, 2008 - March 31, 2011
|
Summary: By using transgenic animal models of Alzheimer's disease, this project seeks to test whether slowing down the activity of a particular molecular pathway can restore cognitive abilities.
More details
Program: Alzheimer's Disease
Award Type: Standard
$400,000
|
|
Cynthia Massaad, Ph.D.
Baylor College of Medicine
Houston, TX
Title:
The Role of Mitochondrial Superoxide in Alzheimer's Pathology
Non-Technical Title:
Identifying a novel antioxidant target for Alzheimer's disease therapy
Duration:
April 1, 2008 - October 31, 2010
Mentor:
Robia Pautler, Ph.D.
Baylor College of Medicine
|
Summary: This project examines the role of antioxidants in mouse models of Alzheimer's disease. The study will examine the pathophysiological basis of the disease using Magnetic Resonance Imaging (MRI). The outcomes of this project will predict ways of using antioxidant therapy to overcome Alzheimer's disease.
More details
Program: Alzheimer's Disease
Award Type: Research Fellowship
$100,000
|
Kathryn Moore, Ph.D.
New York University
New York, NY
Title:
Innate immune signaling in Alzheimer's disease pathogenesis
Non-Technical Title:
Role of the innate immune response in the development of Alzheimer's disease
Duration:
April 1, 2008 - March 31, 2011
|
Summary: This award seeks to study the role of the innate immune system in AD pathogenesis. and the role of Toll-like recceptors in mediating the microglial inflammatory response. Microglia likely play a key role in the clearance of Aß as well as in more chronic inflammatory changes as a result of Aß activation.
More details
Program: Alzheimer's Disease
Award Type: Standard
$265,000
|
Marguerite Prior, Ph.D.
The Cleveland Clinic Foundation
Cleveland, OH
Title:
Inhibition of RTN3 aggregation as a novel therapeutic target to reduce cognitive failure in AD
Non-Technical Title:
Novel therapeutic target to reduce cognitive failure in AD
Duration:
April 1, 2008 - May 31, 2010
Mentor:
Riqiang Yan, Ph.D.
The Cleveland Clinic Foundation
|
Summary: This study hypothesizes that aggregation of a BACE inhibitor (RTN3) may lead to increased levels of amyloid beta. By defining a class of potential inhibitors of RTN3 aggregation, this proposal seeks to determine a new class of therapeutic interventions against Alzheimer's disease.
More details
Program: Alzheimer's Disease
Award Type: Research Fellowship
$100,000
|
Wolfgang Quitschke, Ph.D.
State University of New York at Stony Brook
Stony Brook, NY
Title:
Effect Of Serum-Solubilized Curcumin On Plaques In Alzheimer’s Disease Transgenic Mice
Non-Technical Title:
Effect Of Injectable Derivatives Of The Turmeric Spice On Plaques In AD Transgenic Mice
Duration:
April 1, 2009 - March 31, 2011
|
Summary: Experimentally, curcumin (turmeric spice) has been implicated in resolving and preventing Alzheimer’s disease associated plaques or deposits both in living systems and in test tubes. Epidemiological data suggest that the consumption of curcumin is linked to a lower incidence of Alzheimer’s disease. However, the solubility of curcumin in watery solutions is exceedingly low, which limits its systemic absorption and therapeutic potential. A new method is proposed to treat or prevent amyloid plaque formation associated with Alzheimer’s disease by injection of highly concentrated blood serum-solubilized curcumin.
More details
Program: Alzheimer's Disease
Award Type: Pilot
$104,762
|
Erik Roberson, M.D., Ph.D.
University of Alabama at Birmingham
Birmingham, AL
Title:
Characterizing protective effects of induced tau reduction
Non-Technical Title:
Characterizing effects of reducing tau expression in adulthood
Duration:
April 1, 2010 - March 31, 2012
|
Summary: Tau may serve as an excellent treatment target in Alzheimer’s disease Alzheimer’s disease, and we recently found that genetic elimination of tau had a strong protective effect in mouse models of Alzheimer’s disease. In those studies, tau was absent in the animals starting at conception, and throughout their lives. The proposed research will address the critical question of whether reducing tau expression in adulthood, which is more relevant therapeutically, has similar protective effects.
More details
Program: Alzheimer's Disease
Award Type: Pilot
$150,000
|
Terrone Rosenberry, Ph.D.
Mayo Clinic Jacksonville
Jacksonville, FL
Title:
Detection of cross-linked amyloid-beta oligomers in Alzheimer's disease by mass spectrometry
Non-Technical Title:
Is a specific chemical modification of amyloid beta-peptides important in Alzheimer's disease?
Duration:
April 1, 2008 - June 30, 2010
|
Summary: This study seeks to determine some of the mechanisms by which amyloid beta aggregates and ultimately how these aggregates work to assemble in amyloid plaques. Using a systematic approach, Dr. Rosenberry's team is working on developing ways of studying these aggregates that exist at extremely low concentrations in the brain.
More details
Program: Alzheimer's Disease
Award Type: Pilot
$150,000
